DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil
Figure 1
Comparison of the estimated overall survival according to the risk category with a followup of 120 months: favorable (54.9%), intermediate (39%), and unfavorable (16.7%) ().
